- Europe, like you've never read before -
Saturday, 21 November 2026
No Result
View All Result
  • en ENG
  • it ITA
Eunews
  • Politics
  • World
  • Business
  • News
  • Defence
  • Health
  • Agrifood
  • Other sections
    • Culture
    • Rights
    • Energy
    • Green Economy
    • Finance & Insurance
    • Industry & Markets
    • Media
    • Mobility & Logistics
    • Net & Tech
    • Sports
  • Eunews Newsletter
  • European 2024
    Eunews
    • Politics
    • World
    • Business
    • News
    • Defence
    • Health
    • Agrifood
    • Other sections
      • Culture
      • Rights
      • Energy
      • Green Economy
      • Finance & Insurance
      • Industry & Markets
      • Media
      • Mobility & Logistics
      • Net & Tech
      • Sports
    No Result
    View All Result
    Eunews
    No Result
    View All Result

    Home » Health » New EU rules on medicines: more incentives for innovation and availability monitoring

    New EU rules on medicines: more incentives for innovation and availability monitoring

    The Public Health Committee has given the green light to the agreements reached with the Council at the end of the year. The rapporteur, Dolores Monserrat, who is also vice-president of the EPP, argues that the legislation approved is the "most ambitious piece of EU pharmaceutical legislation ever undertaken"

    Annachiara Magenta</a> <a class="social twitter" href="https://twitter.com/annacmag" target="_blank">annacmag</a> by Annachiara Magenta annacmag
    18 March 2026
    in Health
    Farmaci

    BAYER LABORATORIO SCIENZIATO SCIENZIATI RICERCATRICE RICERCATORE RICERCATORI INDUSTRI FARMACEUTICA PRODUZIONE FARMACI

    Brussels – Improved access to medicines for European citizens; promotion of innovation; simplification of regulatory procedures; enhanced monitoring and management of medicine shortages across the EU. MEPs from the European Parliament’s Committee on Public Health have approved the agreements reached with the Council of the European Union—and thus with the Member States—on the pharmaceutical package (comprising a directive and a regulation). For the European Parliament’s rapporteur on the directive, the Spanish MEP Dolores Monserrat, who is also vice-president of the European People’s Party (EPP), this is the “most ambitious reform of EU pharmaceutical legislation ever undertaken.”

    The European Parliament and the Council have outlined a new regulatory framework designed to balance pharmaceutical innovation with access to treatments, introducing criteria for data protection and market protection. The established framework provides for a standard eight-year period of data protection, during which third parties cannot access product information, followed by a further year of market protection preventing the sale of generic or biosimilar medicines. However, this timeframe may be extended if companies meet specific public interest requirements. To ensure access to medicines across the EU, the package provides for the inclusion of a QR code on the medicine’s packaging: by scanning it, patients can verify the medicine’s authenticity through translations of the name and package leaflet into all EU languages.

    To facilitate the timely entry of generic and biosimilar medicines, the new provisions clarify the scope of the “Bolar” exemption, a derogation from patent law that allows generic and biosimilar companies to conduct studies, clinical trials, and administrative procedures while the originator medicine’s patent is still in force. This measure allows manufacturers to carry out preparatory activities, such as studies, clinical trials, and procedures for obtaining pricing and reimbursement information or participating in tenders, without these activities constituting an infringement of patent rights.

    As part of the fight against bacterial resistance, a transferable data exclusivity voucher for priority antimicrobials has been introduced. This instrument grants an additional twelve months of protection, which may be used once by the marketing authorisation holder or transferred to third parties for other centrally authorised medicinal products. At the same time, antimicrobial management is becoming stricter: a medical prescription is now mandatory for all products in this category, and companies must provide specific management plans and environmental risk assessments. Information for patients is being enhanced through detailed information requirements and the obligation to provide a paper leaflet when the package leaflet is available only in electronic format.

    The modernisation process also involves the internal workings of the European Medicines Agency (EMA), with the aim of speeding up application reviews by adopting a common electronic format. A significant change concerns the validity of marketing authorisations, which will be unlimited by default, eliminating the administrative burden of periodic renewals, whilst retaining the EMA’s power to limit their duration for safety reasons.

    Finally, the European Commission will be able to establish regulatory sandboxes to test innovative therapies under strict supervision. To tackle medicine shortages, marketing authorisation holders are now required to draw up and update prevention plans for prescription medicines. Stock monitoring will take place at both national and EU levels, leading to the creation of a European list of critical shortages to ensure the constant availability of the treatments citizens need.

    English version by the Translation Service of Withub
    Tags: agenzia europea per i medicinaliantimicrobicieuropean speakingmedicinalipharmacipublic health

    Related Posts

    OSPEDALE PEDIATRICO GIOVANNI XXIII  IN OCCASIONE DELLA XIV GIORNATA MONDIALE DELLE MALATTIE RARE LE ASSOCIAZIONI AMARAM APS  ASSIEME ONLUS AID KARTAGENERONLUS VITE DA COLORARE E CENTRO ASCOLTO INCONT-RARE HANNO DONATO DUE CORBEZZOLI CHE ADORNERANNO  LE AIUOLE ANTISTANTI L'INGRESSO DEL PRONTO SOCCORSO  CARTELLO AIUOLA DELLA RARITA'
    Health

    Rare diseases now affect 36 million people. They advance in the EU, while Europe stands still

    15 December 2025
    Marco Mattei Raffaele Topo
    Health

    The appeal of the Italian pharmaceutical industry to national and EU decision-makers: “Let’s create a more attractive market”

    18 September 2025
    Connact
    Health

    Pharma sector key to EU competitiveness. Várhelyi: ‘innovation must reach everyone

    18 September 2025
    map visualization
    Il primo ministro della Gran Bretagna, Andy Burnham, il presidente del Consiglio europeo, Antònio Costa, la presidente della Commissione europea, Ursula von der Leyen, prendono un tè informale al Summit UE-Regno Unito. Crediti: Consiglio dell'Unione europea

    Burnham declares Brexit a failure: “We want a better deal”

    by Iolanda Cuomo
    20 November 2026

    The British Prime Minister is in the Belgian capital for the second EU-UK Summit: “Today’s agreements cover the cost of...

    [Foto: Jérémie Mazenq. Copyright:
European Union , 2024

    Multiannual budget: EU Council reaches agreement in principle on a “stronger” civil protection mechanism

    by Emanuele Bonini emanuelebonini
    20 November 2026

    Member States have agreed on a more efficient emergency and crisis management mechanism. The outcome of the negotiations on the...

    Crediti foto: Sasun Bughdaryan via Unsplash

    EU sees record number of breast cancer prevention and treatment surgeries in 2024

    by Iolanda Cuomo
    20 November 2026

    Brussels – In 2024, there were 560,730 surgeries in the European Union to remove part of a mammary gland (partial excision) or...

    Sessione plenaria del Parlamento europeo a Strasburgo di luglio 2026. Crediti: Parlamento europeo

    EU budget, COP31, the cost-of-living crisis and – at last – a debate on Gaza: the European Parliament’s plenary agenda

    by Annachiara Magenta annacmag
    20 November 2026

    The next multiannual financial framework will dominate the debate among political groups. On Wednesday morning, MEPs will discuss the new...

    • Director’s Point of View
    • Opinions
    • About us
    • Contacts
    • Privacy Policy
    • Cookie policy

    Eunews is a registered newspaper
    Press Register of the Court of Turin n° 27

    Copyright © 2025 - WITHUB S.p.a., Via Savona 127/B, 20144 Milano
    VAT number: 10067080969 - ROC registration number n.30628
    Fully paid-up share capital 50.000,00€

     

    No Result
    View All Result
    • en ENG
    • it ITA
    • Politics
    • Newsletter
    • World politics
    • Business
    • General News
    • Defence & Security
    • Health
    • Agrifood
    • Altre sezioni
      • Culture
      • Rights
      • Energy
      • Green Economy
      • Gallery
      • Finance & Insurance
      • Industry & Markets
      • Media
      • Mobility & Logistics
      • Net & Tech
      • News
      • Opinions
      • Sports
    • Director’s Point of View
    • Draghi Report
    • Eunews Newsletter

    No Result
    View All Result
    • en ENG
    • it ITA
    • Politics
    • Newsletter
    • World politics
    • Business
    • General News
    • Defence & Security
    • Health
    • Agrifood
    • Altre sezioni
      • Culture
      • Rights
      • Energy
      • Green Economy
      • Gallery
      • Finance & Insurance
      • Industry & Markets
      • Media
      • Mobility & Logistics
      • Net & Tech
      • News
      • Opinions
      • Sports
    • Director’s Point of View
    • Draghi Report
    • Eunews Newsletter

    Attention